Summary
162.98 -1.80(-1.09%)07/17/2025
Johnson & Johnson (JNJ)
JNJ reported last earnings on 2025-07-16 after the market. An EPS of $2.77 was observed compared to an estimated EPS of $2.68, resulting in a surprise value of $0.09. A revenue of $23,743 million was observed compared to an estimated revenue of $22,854 million, resulting in a surprise value of $889 Million.
Johnson & Johnson (JNJ)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| 0.41 | 3.88 | 6.96 | 4.39 | 12.70 | 7.48 | 25.56 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | B+ |
| Recommended Rating | Neutral |
| DCF | Buy |
| ROE | Strong Buy |
| ROA | Strong Buy |
| Debt/Equity | Strong Sell |
| P/E | Sell |
| P/B | Sell |
Earnings
| Trading Data | ||
| Close | 163.65 | |
| Open | 163.93 | |
| High | 165.09 | |
| Low | 163.37 | |
| Volume | 6,943,337 | |
| Change | 0.67 | |
| Change % | 0.41 | |
| Avg Volume (20 Days) | 9,241,203 | |
| Volume/Avg Volume (20 Days) Ratio | 0.75 | |
| 52 Week Range | 138.69 - 168.54 | |
| Price vs 52 Week High | -2.90% | |
| Price vs 52 Week Low | 18.00% | |
| Range | 0.00 | |
| Gap Up/Down | -2.94 | |
Profitibility | ||
| Market Capitalization (Mln) | 373,735 | |
| Revenue per share | 27.6483 | |
| Net Income per share | 9.3675 | |
| Dividend Yield | 0.0308 | |
| Dividend Share | 502.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | 17.3984 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
07/18 12:10 EST - zacks.com
J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?
JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.
J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?
JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.
07/18 11:42 EST - proactiveinvestors.com
Spravato sales momentum underscores market potential for psychedelics, atai Life Sciences seen as key beneficiary
Sales of Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray Spravato grew sequentially in the second quarter, marking a positive sign for the broader psychedelics sector, according to Jefferies analysts. Spravato sales grew 29% quarter-over-quarter to $414 million worldwide.
Spravato sales momentum underscores market potential for psychedelics, atai Life Sciences seen as key beneficiary
Sales of Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray Spravato grew sequentially in the second quarter, marking a positive sign for the broader psychedelics sector, according to Jefferies analysts. Spravato sales grew 29% quarter-over-quarter to $414 million worldwide.
07/17 19:47 EST - youtube.com
JNJ gave us a manual on how to spot a stock that can soar after earnings, says Jim Cramer
'Mad Money' host Jim Cramer talks how to react when surprise stock pops happen.
JNJ gave us a manual on how to spot a stock that can soar after earnings, says Jim Cramer
'Mad Money' host Jim Cramer talks how to react when surprise stock pops happen.
07/17 16:37 EST - benzinga.com
Stock Of The Day: Breakout In Johnson & Johnson
Johnson & Johnson JNJ stalled out at resistance around the $165 level. There tends to be resistance at price levels that had previously been resistance.
Stock Of The Day: Breakout In Johnson & Johnson
Johnson & Johnson JNJ stalled out at resistance around the $165 level. There tends to be resistance at price levels that had previously been resistance.
07/17 14:26 EST - marketbeat.com
Want Steady Income? 3 Top Dividend Stocks for July 2025
Earnings season is synonymous with market volatility. Growth-oriented investors may love trading the ups and downs, but more risk-averse investors may look for ways to generate solid returns balanced by steady cash flow.
Want Steady Income? 3 Top Dividend Stocks for July 2025
Earnings season is synonymous with market volatility. Growth-oriented investors may love trading the ups and downs, but more risk-averse investors may look for ways to generate solid returns balanced by steady cash flow.
07/17 12:40 EST - seekingalpha.com
Johnson & Johnson: The Worst Is Baked In
J&J's diversified business, robust pipeline, and strong free cash flow provide stability despite ongoing legal overhang from talcum powder claims. Legal risks remain a near-term headwind, but I believe any settlement will be manageable for J&J's financial strength and present a buying opportunity....
Johnson & Johnson: The Worst Is Baked In
J&J's diversified business, robust pipeline, and strong free cash flow provide stability despite ongoing legal overhang from talcum powder claims. Legal risks remain a near-term headwind, but I believe any settlement will be manageable for J&J's financial strength and present a buying opportunity....
07/17 12:01 EST - zacks.com
ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook
IHE, PPH, XLV, IYH and FTXH could gain as JNJ lifts 2025 outlook and dividend after strong Q2 earnings beat.
ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook
IHE, PPH, XLV, IYH and FTXH could gain as JNJ lifts 2025 outlook and dividend after strong Q2 earnings beat.
07/17 09:32 EST - benzinga.com
Johnson & Johnson Analysts Raise Their Forecasts After Upbeat Earnings
Johnson & Johnson JNJ posted better-than-expected quarterly earnings and raised its FY2025 earnings guidance on Wednesday.
Johnson & Johnson Analysts Raise Their Forecasts After Upbeat Earnings
Johnson & Johnson JNJ posted better-than-expected quarterly earnings and raised its FY2025 earnings guidance on Wednesday.
07/17 08:00 EST - prnewswire.com
Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer
New Drug Application supported by results from the Phase 2b SunRISe-1 study RARITAN, N.J. , July 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:Â JNJ) today announced that the U.S. Food and Drug Administration (FDA) granted Priority Review to the New Drug Application (NDA) filed for TAR-200, an...
Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer
New Drug Application supported by results from the Phase 2b SunRISe-1 study RARITAN, N.J. , July 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:Â JNJ) today announced that the U.S. Food and Drug Administration (FDA) granted Priority Review to the New Drug Application (NDA) filed for TAR-200, an...
07/17 06:05 EST - fool.com
Johnson & Johnson's Healthy 3.3%-Yielding Dividend Is a Very Safe Way to Make Passive Income
Johnson & Johnson (JNJ 6.21%) has been an extremely reliable dividend stock for decades. The healthcare behemoth has raised its payment for 63 straight years, including by 4.8% earlier this year.
Johnson & Johnson's Healthy 3.3%-Yielding Dividend Is a Very Safe Way to Make Passive Income
Johnson & Johnson (JNJ 6.21%) has been an extremely reliable dividend stock for decades. The healthcare behemoth has raised its payment for 63 straight years, including by 4.8% earlier this year.
07/17 04:37 EST - fool.com
Is Johnson & Johnson a Good Dividend Stock to Buy Now?
For decades, Johnson & Johnson (JNJ 6.21%) stock was favored by investors seeking steady gains. Looking at its post-COVID-19 performance, though, steady gains aren't what investors received.
Is Johnson & Johnson a Good Dividend Stock to Buy Now?
For decades, Johnson & Johnson (JNJ 6.21%) stock was favored by investors seeking steady gains. Looking at its post-COVID-19 performance, though, steady gains aren't what investors received.
07/16 18:01 EST - fool.com
3 Top Dividend Stocks Yielding More Than 3% That You Shouldn't Hesitate to Buy Right Now
With the S&P 500 back in rally mode, the dividend yield on the broad market index is falling. It was recently down to around 1.2%, which is approaching its record low last hit a quarter-century ago.
3 Top Dividend Stocks Yielding More Than 3% That You Shouldn't Hesitate to Buy Right Now
With the S&P 500 back in rally mode, the dividend yield on the broad market index is falling. It was recently down to around 1.2%, which is approaching its record low last hit a quarter-century ago.
07/16 17:40 EST - investopedia.com
S&P 500 Gains and Losses Today: Johnson & Johnson Stock Jumps; Universal Health Services Shares Slide
Major U.S. equities indexes ticked higher Wednesday as President Donald Trump refuted reports that he is planning the immediate dismissal of Federal Reserve Chair Jerome Powell and questions about his legal ability to do so.
S&P 500 Gains and Losses Today: Johnson & Johnson Stock Jumps; Universal Health Services Shares Slide
Major U.S. equities indexes ticked higher Wednesday as President Donald Trump refuted reports that he is planning the immediate dismissal of Federal Reserve Chair Jerome Powell and questions about his legal ability to do so.
07/16 16:26 EST - zacks.com
Johnson & Johnson (JNJ) Q2 Earnings and Revenues Top Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.82 per share a year ago.
Johnson & Johnson (JNJ) Q2 Earnings and Revenues Top Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.82 per share a year ago.
07/16 16:20 EST - zacks.com
Johnson & Johnson (JNJ) Surpasses Q2 Earnings and Revenue Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.82 per share a year ago.
Johnson & Johnson (JNJ) Surpasses Q2 Earnings and Revenue Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.82 per share a year ago.
07/16 16:16 EST - marketbeat.com
JNJ's Stock Price Is Back in Rally Mode—The Time to Buy Is Now
After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson's NYSE: JNJ stock price is back in rally mode. It is still early in the game, but the Q2 results affirm that growth is back, acceleration is happening and is expected to continue in the back half...
JNJ's Stock Price Is Back in Rally Mode—The Time to Buy Is Now
After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson's NYSE: JNJ stock price is back in rally mode. It is still early in the game, but the Q2 results affirm that growth is back, acceleration is happening and is expected to continue in the back half...
07/16 16:00 EST - youtube.com
JNJ Technicals & Takeaways After Earnings, Healthcare Reaching Key Levels
Johnson & Johnson (JNJ) shares popped after earnings that showed strength for the healthcare company. Rick Ducat dives into the stock chart to highlight how Johnson & Johnson is tapping a notable resistance level backed by bullish signals.
JNJ Technicals & Takeaways After Earnings, Healthcare Reaching Key Levels
Johnson & Johnson (JNJ) shares popped after earnings that showed strength for the healthcare company. Rick Ducat dives into the stock chart to highlight how Johnson & Johnson is tapping a notable resistance level backed by bullish signals.
07/16 15:36 EST - seekingalpha.com
Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript
Johnson & Johnson (NYSE:JNJ ) Q2 2025 Earnings Conference Call July 16, 2025 8:30 AM ET Company Participants Darren Snellgrove - Corporate Participant Jennifer L. Taubert - Executive VP & Worldwide Chairman of Innovative Medicine Joaquin Duato - CEO & Chairman John C.
Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript
Johnson & Johnson (NYSE:JNJ ) Q2 2025 Earnings Conference Call July 16, 2025 8:30 AM ET Company Participants Darren Snellgrove - Corporate Participant Jennifer L. Taubert - Executive VP & Worldwide Chairman of Innovative Medicine Joaquin Duato - CEO & Chairman John C.
07/16 15:20 EST - 247wallst.com
2 Dividend Giants Every Passive Income Investors Should Own
It's never been easier as a passive income investor to give your yield a bit of a jolt with the rise of covered call (and premium income) ETFs that trade off a bit of upside potential for some premiums.
2 Dividend Giants Every Passive Income Investors Should Own
It's never been easier as a passive income investor to give your yield a bit of a jolt with the rise of covered call (and premium income) ETFs that trade off a bit of upside potential for some premiums.
07/16 14:56 EST - fool.com
Johnson & Johnson Lifts 2025 Outlook
Johnson & Johnson (JNJ 5.93%) reported Q2 2025 earnings on July 16, 2025, posting sales of $23.7 billion (up 4.6%), with adjusted EPS of $2.77 and net earnings of $5.5 billion. Management raised full-year 2025 sales guidance by $2 billion and adjusted EPS guidance by $0.25, citing robust...
Johnson & Johnson Lifts 2025 Outlook
Johnson & Johnson (JNJ 5.93%) reported Q2 2025 earnings on July 16, 2025, posting sales of $23.7 billion (up 4.6%), with adjusted EPS of $2.77 and net earnings of $5.5 billion. Management raised full-year 2025 sales guidance by $2 billion and adjusted EPS guidance by $0.25, citing robust...